Press Releases

Date Title and Summary Additional Formats
Toggle Summary Mylan's Apomorphine NDA Advances in FDA Review Process
Mylan's Apomorphine NDA Advances in FDA Review Process PITTSBURGH--(BUSINESS WIRE)--July 10, 2003--Mylan Laboratories Inc. (NYSE:MYL) announced today that its subsidiary, Bertek Pharmaceuticals Inc., has received an approvable letter from the Food and Drug Administration (FDA) for its New Drug
View HTML
Toggle Summary Mylan Acknowledges FDA Letter, Which Will Not Impact the Commercial Status of Amnesteem
Mylan Acknowledges FDA Letter, Which Will Not Impact the Commercial Status of Amnesteem PITTSBURGH--(BUSINESS WIRE)--June 19, 2003--Mylan Laboratories' (NYSE:MYL) brand subsidiary, Bertek Pharmaceuticals received an Untitled Letter from the United States Food and Drug Administration (FDA) regarding
View HTML
Toggle Summary Mylan Receives FDA Approval for Mirtazapine Tablets
Mylan Receives FDA Approval for Mirtazapine Tablets PITTSBURGH, Jun 19, 2003 (BUSINESS WIRE) -- Mylan Laboratories Inc. (NYSE:MYL) announced today that the U.S. Food and Drug Administration has granted final approval for its Abbreviated New Drug Application for Mirtazapine Tablets in 15 mg, 30 mg
View HTML
Toggle Summary Mylan Declares Regular Quarterly Cash Dividend
Mylan Declares Regular Quarterly Cash Dividend PITTSBURGH--(BUSINESS WIRE)--June 16, 2003--Mylan Laboratories Inc. (NYSE:MYL) announced today that the regular quarterly cash dividend of $0.0333 per share will be paid on July 15, 2003, to shareholders of record on June 30, 2003.
View HTML
Toggle Summary Mylan Announces Approval for Omeprazole Delayed-release Capsules
Mylan Announces Approval for Omeprazole Delayed-release Capsules PITTSBURGH, Jun 2, 2003 (BUSINESS WIRE) -- Mylan Laboratories Inc. (NYSE:MYL) announced today that the U.S. Food and Drug Administration (FDA) has granted final approval for its Abbreviated New Drug Application (ANDA) for Omeprazole
View HTML
Toggle Summary Mylan Reports Record EPS, Revenues and Net Earnings For the Fourth Quarter and Fiscal 2003
Mylan Reports Record EPS, Revenues and Net Earnings For the Fourth Quarter and Fiscal 2003 PITTSBURGH--(BUSINESS WIRE)--May 8, 2003--Mylan Laboratories Inc. (NYSE: MYL) Financial Highlights -- Record diluted earnings per share of $1.45 for fiscal 2003 and $.40 for the fourth quarter, compared to
View HTML
Toggle Summary Mylan Announces Fourth Quarter and Fiscal 2003 Earnings Release Date and Conference Call
Mylan Announces Fourth Quarter and Fiscal 2003 Earnings Release Date and Conference Call CANONSBURG, Pa., Apr 28, 2003 (BUSINESS WIRE) -- Mylan Laboratories Inc. (NYSE: MYL) announced today that it will release its fourth quarter and fiscal 2003 financial results before the market opens on
View HTML
Toggle Summary Mylan to Receive $22.5 Million Related to Litigation Settlements
Mylan to Receive $22.5 Million Related to Litigation Settlements PITTSBURGH, Pa.--(BUSINESS WIRE)--April 11, 2003--Mylan Laboratories Inc. (NYSE:MYL) announced today that it has agreed to a tentative settlement under which it will receive $12.5 million from Aventis Pharmaceuticals, Inc.
View HTML
Toggle Summary Mylan Relocates Corporate Headquarters
Mylan Relocates Corporate Headquarters PITTSBURGH, Pa.--(BUSINESS WIRE)--April 10, 2003--Mylan Laboratories Inc. (NYSE: MYL) a leading developer, manufacturer and marketer of generic and proprietary pharmaceuticals announced today the relocation of its Corporate Headquarters to a new
View HTML
Toggle Summary Mylan Announces Filing of Modafinil ANDA
Mylan Announces Filing of Modafinil ANDA PITTSBURGH--(BUSINESS WIRE)--April 2, 2003--Mylan Laboratories Inc. (NYSE: MYL) announced today that it received confirmation from the FDA in February, 2003 that the Company's Modafinil (Provigil ® ) ANDA has been accepted for filing.
View HTML